Adamis Pharmaceuticals Statistics Share Statistics Adamis Pharmaceuticals has 9.36M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 9.36M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 9.14M Failed to Deliver (FTD) Shares 2,802 FTD / Avg. Volume 0.09%
Short Selling Information The latest short interest is 103.59K, so 0% of the outstanding
shares have been sold short.
Short Interest 103.59K Short % of Shares Out n/a Short % of Float 1.12% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.97 and the forward
PE ratio is null.
Adamis Pharmaceuticals's PEG ratio is
0.04.
PE Ratio -0.97 Forward PE n/a PS Ratio 5.33 Forward PS n/a PB Ratio -31.39 P/FCF Ratio -0.95 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Adamis Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.81,
with a Debt / Equity ratio of -0.42.
Current Ratio 0.81 Quick Ratio 0.7 Debt / Equity -0.42 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage -567.9
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $432.37K Profits Per Employee $-2.38M Employee Count 11 Asset Turnover 0.44 Inventory Turnover 4.99
Taxes Income Tax 2K Effective Tax Rate -0.01%
Stock Price Statistics The stock price has increased by 24.98% in the
last 52 weeks. The beta is 1.28, so Adamis Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.28 52-Week Price Change 24.98% 50-Day Moving Average 1 200-Day Moving Average 6.45 Relative Strength Index (RSI) 43.5 Average Volume (20 Days) 3,113,594
Income Statement In the last 12 months, Adamis Pharmaceuticals had revenue of 4.76M
and earned -26.2M
in profits. Earnings per share was -12.24.
Revenue 4.76M Gross Profit -1.43M Operating Income -25.06M Net Income -26.2M EBITDA -24.27M EBIT -1.16B Earnings Per Share (EPS) -12.24
Full Income Statement Balance Sheet The company has 1.08M in cash and 342.56K in
debt, giving a net cash position of 738.8K.
Cash & Cash Equivalents 1.08M Total Debt 342.56K Net Cash 738.8K Retained Earnings -304.56M Total Assets 8.96B Working Capital -5.59B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -25.9M
and capital expenditures -680.42K, giving a free cash flow of -26.58M.
Operating Cash Flow -25.9M Capital Expenditures -680.42K Free Cash Flow -26.58M FCF Per Share -12.42
Full Cash Flow Statement Margins Gross margin is -30.1%, with operating and profit margins of -526.88% and -550.86%.
Gross Margin -30.1% Operating Margin -526.88% Pretax Margin -550.82% Profit Margin -550.86% EBITDA Margin -510.24% EBIT Margin -526.88% FCF Margin -558.88%
Dividends & Yields ADMP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ADMP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 22, 2023. It was a
backward
split with a ratio of 1:70.
Last Split Date May 22, 2023 Split Type backward Split Ratio 1:70
Scores Altman Z-Score -51.31 Piotroski F-Score 4
